Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,794 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Genetic Change Clear all

Conditions: Carcinoid Neuroendocrine Cancer
Interventions: Not listed
Lead sponsor: Rutgers University; Other
Eligibility: 12 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Tumors With CDK4/6 Pathway Activation
Interventions: LEE011; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 61
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more

Conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Interventions: Sotorasib, Ladarixin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Garden City, New York • Mineola, New York • New Hyde Park, New York + 1 more

Conditions: Immunologic Deficiency Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
Interventions: Olaparib, ASTX727; Drug
Lead sponsor: Varun Monga, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Inavolisib, Ribociclib, Letrozole, Giredestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • Germantown, Tennessee + 3 more

Conditions: Cystic Fibrosis
Interventions: standardized turmeric root extract; Drug
Lead sponsor: Ramsey, Bonnie, MD; Individual
Eligibility: 18 Years to 40 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Genetic Predisposition to Disease
Interventions: Family History education, Patient Ambassador; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 40 Years and older · Female only
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
Interventions: Olaparib 300mg tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 81
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more

Conditions: Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 9,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 213
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more

Conditions: Chronic Low Back and Leg Pain
Interventions: Not listed
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Edina, Minnesota • Garland, Texas

Conditions: Breast Cancer
Interventions: Inavolisib, Ribociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Anaheim, California • Palo Alto, California • Jacksonville, Florida + 8 more

Conditions: Progranulin Mutation Carriers
Interventions: Nimodipine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stage IB-IIIA Non-small Cell Lung Carcinoma
Interventions: AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 23
States / cities: Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: mDC3/8-KRAS Vaccine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7, PD-L1 Gene Mutation, Advanced Treatment-Naïve PD-L1, Sitravatinib, Pembrolizumab
Interventions: Sitravatinib, Pembrolizumab; Drug
Lead sponsor: Sarah Goldberg; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: NSCLC
Interventions: GI-4000; Biological
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia
Interventions: Acalabrutinib, Venetoclax, Chemoimmunotherapy, Obinutuzumab; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 984 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Redondo Beach, California • Fort Wayne, Indiana + 12 more

Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 11
States / cities: Hays, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more

Conditions: Salivary Gland Cancer, HER2 Gene Mutation
Interventions: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 13
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 8 more

Conditions: Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions: Osimertinib, Osimertinib + Chemotherapy; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 146
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more

Conditions: Myelodysplastic Syndromes
Interventions: FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software; Drug · Other · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions: Gilteritinib, Vyxeos; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: XIAP Deficiency, NLRC4-MAS
Interventions: Tadekinig alfa; Drug
Lead sponsor: AB2 Bio Ltd.; Industry
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: La Jolla, California • Gainsville, Florida • Atlanta, Georgia + 5 more

Search by objective public record fields.

Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Genetic Basis of Primary Immunodeficiencies

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis

Family History and Breast Cancer Education Trial

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Spinal Cord Stimulation Research Study

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

DC Vaccine in Pancreatic Cancer

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension